key: cord-0955943-s0s9wgzn
authors: Huh, Hee Jae; Hong, Ki Ho; Kim, Taek Soo; Song, Sang Hoon; Roh, Kyoung Ho; Lee, Hyukmin; Kwon, Gye Cheol
title: Surveillance of Coronavirus Disease 2019 (COVID-19) Testing in Clinical Laboratories in Korea
date: 2021-03-01
journal: Ann Lab Med
DOI: 10.3343/alm.2021.41.2.225
sha: de2910d192867233eabbf9bb9a2d1ff09f956e44
doc_id: 955943
cord_uid: s0s9wgzn

In response to the ongoing coronavirus disease 2019 (COVID-19) pandemic, an online laboratory surveillance system was established to monitor severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) real-time reverse transcription-PCR (rRT-PCR) testing capacities and results. SARS-CoV-2 rRT-PCR testing data were collected from 97 clinical laboratories, including 84 medical institutions and 13 independent clinical laboratories in Korea. We assessed the testing capacities to utilize SARS-CoV-2 rRT-PCR based on surveillance data obtained from February 7th to June 4th, 2020 and evaluated positive result characteristics according to the reagents used and sample types. A total of 1,890,319 SARS-CoV-2 rRT-PCR testing were performed, 2.3% of which were positive. Strong correlations were observed between the envelope (E) gene and RNA-dependent RNA polymerase (RdRp)/nucleocapsid (N) genes threshold cycle (Ct) values for each reagent. No statistically significant differences in gene Ct values were observed between the paired upper and lower respiratory tract samples, except in the N gene for nasopharyngeal swab and sputum samples. Our study showed that clinical laboratories in Korea have rapidly expanded their testing capacities in response to the COVID-19 outbreak, with a peak daily capacity of 34,193 tests. Rapid expansion in testing capacity is a critical component of the national response to the ongoing pandemic.

The ongoing coronavirus disease 2019 (COVID-19) pandemic began in December 2019 in Wuhan, China, with more than 13,824,739 confirmed cases as of July 18th, 2020 [1] . In Korea, the first COVID-19 case was confirmed on January 20th, 2020. Rapid viral transmission during the early phase of CO-VID-19 has highlighted the importance of laboratory diagnosis [2, 3] . Molecular testing is the reference standard for COVID-19 diagnosis, and real-time reverse transcription-PCR (rRT-PCR) is the preferred one [2, 4, 5] . The ability of clinical laboratories to perform an appropriate molecular testing for severe acute respiwww.annlabmed.org https://doi.org/10.3343/alm.2021.41.2.225 ratory syndrome coronavirus 2 (SARS-CoV-2) detection is critical for an effective response to the ongoing pandemic. Rapid response system, including an emergency use authorization (EUA) system for emerging infectious diseases, were established by the Korean Centers for Disease Control and Prevention (KCDC), Korean Society for Laboratory Medicine (KSLM), and the Korean Association of External Quality Assessment Service [6, 7] . The first commercial rRT-PCR assay for detecting SARS-CoV-2 was granted EUA by the Ministry of Food and Drug Safety in Korea on February 4th, 2020, and SARS-CoV-2 rRT-PCR testing by clinical laboratories began by February 7th, 2020. However, as the clinical performance of this assay reagent had not been fully evaluated, stringent and continuous quality control was required [7] [8] [9] . Therefore, KSLM COVID-19 Task Force established an online laboratory surveillance system to monitor SARS-CoV-2 rRT-PCR testing capacities and results. We analyzed the surveillance data obtained using this system from February 7th to June 4th, 2020.

SARS-CoV-2 rRT-PCR data were collected from 97 clinical laboratories, including 84 medical institutions and 13 independent clinical laboratories; each laboratory submitted the data to KSLM daily beginning from February 7th, 2020. Public health laboratories, such as the KCDC and local government laboratories, were excluded from this study. Submitted data included: (1) the number of tests performed, including the number that gave positive, negative, and invalid/indeterminate results for SARS-CoV-2, with invalid denoting "failure of both internal control and target gene amplification" and indeterminate denoting that "only some genes were amplified"; (2) detailed information on each positive result, including sample type, assay reagent and equipment used, and threshold cycle (Ct) values for each target gene; and (3) parallel test results to confirm the acceptability of new reagent lot. We collected and reviewed the submitted data once daily and checked errors to ensure data quality. The Institutional Review Board (IRB) of the National Health Insurance Medical Center, Goyang, Korea (IRB No. NHIMC 2020-04-025) approved the study.

We analyzed Spearman correlation to examine the associations between the Ct values of genes. We used the Wilcoxon signed-rank test to compare the Ct values of paired upper respiratory tract (URT) and lower respiratory tract (LRT) samples with Bonferroni correction for multiple comparisons. P < 0.05 was considered significant. Statistical analyses were performed using the MedCalc Statistical Software version 19.2.1 (MedCalc Software Ltd, Ostend, Belgium).

In total, 1,890,319 SARS-CoV-2 rRT-PCR testing was performed, 2.3% of which were positive ( Table 1 ). The testing number and participating laboratories significantly increased by the third week of the study period (February 7th to June 4th, 2020), proportionate to the increase in confirmed cases; with over 70,000 testing being performed weekly after the initial two weeks, the daily testing capacity (34,193 tests) peaked on May 29th, 2020 (Fig. 1) .

Of the positive results, 13,006 results were initially obtained from newly diagnosed COVID-19 patients. Majority of the tests were conducted using the PowerChek 2019-nCoV Real-time PCR Kit (Kogenebiotech, Seoul, Korea), targeting the envelope (E) and RNA-dependent RNA polymerase (RdRp) genes, and the Allplex 2019-nCoV Assay (Seegene, Seoul, Korea), targeting the E, RdRp, and nucleocapsid (N) genes; these were the first and second commercial assays to receive EUA, respectively (Supplemental Data Table S1 ). The parallel test results showed low lot-to-lot reagent variation (Supplemental Data Surveillance for emerging pathogens is a common practice; however, daily surveillance is uncommon [10, 11] . The laboratory-based SARS-CoV-2 surveillance system in our study can provide daily laboratory data for monitoring SARS-CoV-2 rRT-PCR testing results in Korea and is being used successfully in a timely fashion. Our study showed that clinical laboratories in Korea responded quickly to the COVID-19 outbreak, with SARS-CoV-2 rRT-PCR testing beginning 16 days after the first confirmed case in the country, and that the testing capacity in- Recent studies have reported that SARS-CoV-2 detection sensitivity is greater for LRT samples than for URT samples [12] [13] [14] [15] . Using paired sample analysis, Lin, et al. [14] demonstrated that the detection rates of SARS-CoV-2 for sputum samples were significantly higher than those for throat swabs. In our study, paired sample analysis, with positive results from both URT and LRT samples, showed that the Ct value differences between sample types were generally not significant. Although the N gene Ct value differences between NPS and sputum were significant, the median Ct difference (0.49) was low. As these results were derived from initial positive results from newly diagnosed COVID-19 patients, it is possible that several patients were paucisymptomatic or asymptomatic, without productive sputum.

This study has several limitations. We have reported not the number of COVID-19 patients but the number of SARS-CoV-2 rRT-PCR testing. Additionally, we did not collect clinical information, as the study was based on laboratory surveillance data regarding testing capacities and positive result details. In addition, detailed information, such as sample type, was not available for all negative results.

In summary, this laboratory surveillance report for SARS-CoV-2 rRT-PCR testing provided a timely assessment of testing capacities of clinical laboratories and positive result characteristics, according to sample type and assays, for the first few months of the COVID-19 outbreak in Korea. Clinical laboratories rapidly expanded their testing capacity in response to the CO-VID-19 outbreak, with a peak daily testing capacity of 34,193 tests. This rapid expansion in testing capacity is a critical component of the national response to the ongoing pandemic.

World Health Organization. Coronavirus disease (COVID-19) pandemic

Diagnostic testing for severe acute respiratory syndrome-related coronavirus 2: a narrative review

Transmission of 2019-nCoV infection from an asymptomatic contact in Germany

Laboratory diagnosis of COVID-19: current issues and challenges

COVID-19 testing in South Korea: current status and the need for faster diagnostics

Preparedness and rapid implementation of external quality assessment helped quickly increase COVID-19 testing capacity in the Republic of Korea

Guidelines for laboratory diagnosis of coronavirus disease 2019 (COVID-19) in Korea

Quality of ribonucleic acid extraction for real-time reverse transcription-PCR (rRT-PCR) of SARS-CoV-2: importance of internal control monitoring

COV-ID-19 molecular testing in Korea: practical essentials and answers from experts based on experiences of emergency use authorization assays

Survey of clinical laboratory practices for 2015 Middle East Respiratory Syndrome coronavirus outbreak in the Republic of Korea

A new laboratory-based surveillance system (Respiratory DataMart System) for influenza and other respiratory viruses in England: results and experience from

Detection of SARS-CoV-2 in different types of clinical specimens

Viral load of SARS-CoV-2 in clinical samples

Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-CoV-2)-infected pneumonia (COV-ID-19)

SARS-CoV-2 detection in different respiratory sites: a systematic review and meta-analysis

We thank the clinical laboratories that participated in the prospective surveillance program.

TSK, SHS, and GCK were involved in study organization and data collection; HJH and KHH interpreted the data and wrote the first draft of the manuscript; and HL and KHR designed the study and composed the final draft of the manuscript. All authors have read the final manuscript and approved this submission.

No potential conflicts of interest relevant to this article were reported.

None declared.